Report
EUR 14.31 For Business Accounts Only

HUALAN BIOLOGICAL sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of HUALAN BIOLOGICAL (CN), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date January 4, 2022, the closing price was CNY 29.48 and its potential was estimated at CNY 34.97.
Underlying
Hualan Biological Engineering Inc. Class A

Hualan Biological Engineering is engaged in the production and sale of biotechnological and blood products. Co.'s products are classified into four categories: plasma infusion products, such as albumin prepared from human plasma; immunization products, including human immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin and human immunoglobulin (PH4) for intravenous injection; coagulation factor products, including lyophilized human prothrombin complex concentrates and lyophilized human coagulation factor VIII; and wound healing products, such as lyophilized fibrin sealants for surgery.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch